He points to a randomized clinical trial where the P11-4 peptide was tested for helping teeth rebuild mineral. Results are his to describe.
Recap by typeshit. Post by Dr. Thomas Ichim on X.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
BusinessWorld Online covers a Lilly weight loss drug still in clinical trials. Few details were given beyond the headline.
A short social post says drugs like Ozempic may lower heart attack and stroke risk, possibly beyond what weight loss alone explains.
Dr. Woo points to the official position of the AAO and NANOS on whether routine eye exams just to check for NAION are needed.
The Economic Times reports beauty companies are building treatments for facial sagging tied to rapid weight loss, chasing demand from GLP-1 users.
Loading…